You are here

  • Home
  • Archive
  • Volume 2, Issue 2
  • Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial

Article metrics

Article menu

Download PDFPDF

Rheumatoid arthritis
Original article
Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial

 

Online download statistics by month:

Online download statistics by month: September 2016 to September 2024

AbstractFullPdf
Sep 2016487212
Oct 2016425159174
Nov 20161685480
Dec 20161478580
Jan 2017241842
Feb 201732324
Mar 201704146
Apr 201707932
May 201708234
Jun 2017416731
Jul 2017696845
Aug 2017444221
Sep 2017716635
Oct 2017525138
Nov 2017898532
Dec 2017989818
Jan 2018969626
Feb 2018675727
Mar 2018575614
Apr 2018595932
May 2018464814
Jun 2018373612
Jul 2018565417
Aug 2018424318
Sep 2018343424
Oct 2018525424
Nov 20181071079
Dec 201816416415
Jan 201912112011
Feb 201912812519
Mar 2019646118
Apr 2019363628
May 2019333312
Jun 2019434418
Jul 2019302924
Aug 2019282714
Sep 2019272514
Oct 2019373913
Nov 2019454516
Dec 2019595926
Jan 2020383812
Feb 2020585829
Mar 2020565321
Apr 2020494916
May 2020424210
Jun 2020262032
Jul 2020645224
Aug 2020504617
Sep 2020755626
Oct 2020504218
Nov 2020695511
Dec 2020524410
Jan 2021957012
Feb 2021786817
Mar 2021735912
Apr 2021525313
May 2021595310
Jun 202160609
Jul 2021434314
Aug 2021404016
Sep 2021303010
Oct 2021726433
Nov 2021292017
Dec 202128185
Jan 2022473214
Feb 202220173
Mar 2022979512
Apr 2022948810
May 202213413116
Jun 2022877913
Jul 202260548
Aug 2022998914
Sep 2022818211
Oct 2022665611
Nov 202271558
Dec 2022689812
Jan 202380897
Feb 2023666415
Mar 2023625417
Apr 2023454614
May 2023716421
Jun 2023847610
Jul 2023666616
Aug 2023585610
Sep 202349457
Oct 2023574812
Nov 202362365
Dec 2023564811
Jan 202415164
Feb 2024362919
Mar 2024453021
Apr 2024565614
May 2024353310
Jun 2024544416
Jul 20241101016
Aug 2024424712
Sep 2024414010
Total614956381972